TLDR
- Shares of Clorox tumbled to a fresh 52-week low of $88.38 after initially touching $91.00, declining 27.25% year-over-year
- Third quarter FY2026 earnings per share reached $1.64, surpassing consensus by $0.10, though full-year sales outlook was reduced
- The company now anticipates approximately 6% decline in net sales for the full fiscal year 2026
- Major Wall Street firms including Goldman Sachs, UBS, Morgan Stanley, and Evercore ISI lowered their price objectives
- Analyst sentiment remains subdued despite the quarterly earnings outperformance
Shares of Clorox (CLX) plummeted to a new 52-week low of $91.00 on May 1, subsequently declining further to $88.38. The stock has shed 27.25% of its value over the trailing twelve months.
The sharp selloff followed the company’s April 30 release of third quarter FY2026 results and a downward revision to its annual projections.
At first glance, the quarterly performance appeared solid. Adjusted earnings per share totaled $1.64, exceeding Wall Street’s consensus estimate of $1.55 by ten cents. Net revenue reached $1.67 billion, matching analyst expectations.
However, the forward-looking guidance painted a more concerning picture. Management now anticipates net sales will contract by approximately 6% throughout fiscal year 2026—a significant revision from earlier projections.
The company also lowered its adjusted earnings per share outlook for the complete fiscal year to a range of $5.45 to $5.65, down from the previously communicated range of $5.95 to $6.30.
Shares retreated roughly 2% in immediate trading following the announcement.
Wall Street Responds with Lower Price Objectives
The diminished outlook prompted several prominent investment banks to reduce their price targets on the stock.
Goldman Sachs lowered its target price to $83 from $94, explicitly attributing the adjustment to the weakened guidance framework.
UBS reduced its objective to $96 from $110 while maintaining its Neutral stance. Morgan Stanley similarly decreased its target to $97 from $110, highlighting headwinds in specific product segments.
Everest ISI brought down its target to $110 from $115, noting that third quarter performance benefited from the elimination of royalty payments associated with the Glad brand—a non-recurring boost unlikely to persist.
Fundamental Metrics Present Complex Outlook
The company’s price-to-earnings multiple currently stands at 15.76x, which certain market observers consider reasonable relative to current profitability. According to InvestingPro analysis, the shares appear undervalued at present trading levels.
GF Score assigns CLX a rating of 68 out of 100. While profitability metrics score favorably at 7/10, growth measures register just 1/10—a red flag in the highly competitive consumer packaged goods sector.
Financial strength receives a 4/10 rating, suggesting potential vulnerabilities in balance sheet management and liquidity generation.
Management indicated that the recently completed GOJO acquisition should provide some revenue offset to the anticipated decline, though the overall commentary remained measured.
Insider transaction activity over the past year has been minimal—two purchase transactions and one sale, with the sale representing approximately $1.86 million in value.
The company’s market capitalization now stands at roughly $11.66 billion, representing a substantial decrease from valuations seen twelve months earlier.
The latest 52-week low of $88.38 represents the most recent milestone in a stock that has experienced persistent downward pressure throughout the current fiscal period.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
